TEST:

Breast Cancer Index®

No breast cancer index needed. B21 gave us this answer years ago, EUROPA and others will give us average treatment effect for 5 y vs 5 days in terms of QoL. We had just better beware of bad biomarker research for breast (alliteration, ☑️) ()

Watch Chair of Medicine Ruth O'Regan, MD, (@oreganruth) discuss using the #BreastCancer Index as a prognostic tool, and phase 3 SOFT trials for patients with HR+ breast cancer. @OncLive @WilmotCancer #Oncology https://t.co/ZM9nkauu4R ()

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from the addition of ovarian function suppression. @oreganruth @UR_Med #bcsm https://t.co/Aahqqnudcs ()

The Breast Cancer Index test reliably identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from the addition of ovarian function suppression. @oreganruth @UR_Med #bcsm https://t.co/AalMezysDv ()

In the SOFT trial, the BCI test accurately identified premenopausal women undergoing adjuvant endocrine therapy for early-stage, HR+ breast cancer who would derive benefit from adding ovarian function suppression. #bcsm #SABCS22 | @oreganruth @jenreadlynn https://t.co/oehv4LIOje ()

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O'Reagan - What Can the SOFT Trial Reveal For Premenopausal Women with Early-Stage HR+ Breast Cancer? @oreganruth @URMC_DeptMed #SABCS22 #BreastCancer #OncoTwitter Watch and Share the Article Here: https://t.co/0sBipwZyaL ()

Make your way to the back of the #SABCS exhibit hall to hear from Dr. Young, @DrVKGadi and @oreganruth on the predictive power of the Breast Cancer Index H/I Biomarker! ()

#BreastCancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy #URochesterResearch from chair of Medicine @oreganruth, featured in @OncLive ()

Ruth O’Regan, MD, on Evaluation of the Breast Cancer Index in Early-Stage Breast Cancer https://t.co/jd2KZxSYFm #bcsm #breastcancer #oncology #SABCS22 #SABCS2022 @SABCSSanAntonio @oreganruth @URMC_DeptMed @URMC_Medicine ()

Breast Cancer Index: Predict Treatment SABCS 2022 Ruth O'Reagan - What Can the SOFT Trial Reveal For Premenopausal Women with Early-Stage HR+ Breast Cancer? @oreganruth @URMC_DeptMed #SABCS22 #BreastCancer #OncoTwitter Watch and Share the Video Here: https://t.co/Mpy9nG9cHG ()

Breast Cancer Index Risk Scores Are Prognostic for Premenopausal Women With HR+ Breast Cancer Receiving Adjuvant Endocrine Therapy @oreganruth @UR_Med @SABCSSanAntonio #SABCS #bcsm https://t.co/g8AKZrc83K ()

術後内分泌療法を受けた閉経前ホルモン受容体陽性 #乳がん で、遺伝子発現に基づくバイオマーカーである #BreastCancerIndex ()

6. Breast Cancer Index in premenopausal, HR+, LN -from SOFT trial by @oreganruth from @WilmotCancer - Prognostic tool - OFS +ET benefits most in BCI low risk premenopausal patients - What would you do for BCI high-risk? - Poll by @DrSGraff https://t.co/LzxTNwQuN6 8/11 ()

@oreganruth of @URMC_DeptMed shared results from the “Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial” #SABCS22 ()

I had the opportunity of participating at the conference “Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial” in the General Session 1 this evening at @SABCSSanAntonio , Incredible work by MD Ruth M. O’Regan. 🙌🏼👏🏼🩺 ()

#BCI Breast Cancer Index prediction benefit for extended endocrine therapy and prevention late recurrence: #SOFT trial @oreganruth #SABCS2022. May be very helpful marker to decide extended Endocrine therapy @pollyniravath ()

Hard to explain results of Breast cancer index as a predictive biomarker of OFS in SOFT trial. BCI is predictive of OFS benefit for BCI-Low tumo but not for BCI-High. #SABCS2022 ()

BCI assay in SOFT. BCI low (all low grade) 🔼 benefit from OFS/AI. BCI high do not. @hoperugo makes important point in Q&A, however. Hard to reconcile with IDEAL study (longer ET 🔼BCI high), or fit with 🔼 benefit to OFS in biologically higher risk tumors. #SABCS22 ()

…I’m a bit confused here on prognostic & predictive value of #BreastCancer Index in premenopausal patients enrolled in #SOFT trial…need help from experts: results are the opposite than expected @SABCSSanAntonio #SABCS22 @OncoAlert @prat_aleix @c_sotiriou @DrHBurstein @LoiSher ()

@oreganruth presenting on Breast Cancer Index in premenopausal patients with HR+ BC from SOFT trial. BCI(H/I) LOW predictive for benefit from E+OFS vs T+OFS but BCI (H/I) HIGH not predictive. #SABCS22 ()

Breast cancer index and SOFT trial . Can we predict who will benifit more from OFS ? @OncoAlert @SABCSSanAntonio #sabcs22 ()

The Breast Cancer Index genomic assay may predict long-term prognosis and benefit from ovarian suppression therapy in premenopausal patients with hormone receptor-positive early-stage breast cancer, according to results presented at #SABCS22. https://t.co/0z3jIuwK2i @oreganruth ()

How can Breast Cancer Index help inform treatment decisions? Drs. Joyce O'Shaughnessy (@BCJoyceO), Mark Pegram, and @DrVKGadi discuss a challenging case for consideration in recommending extended endocrine therapy: https://t.co/37PkCNswwQ #breastcancerindex #casestudy ()

Risk of recurrence is independent of whether a patient is likely to benefit from extended endocrine therapy. Drs. Mark Pegram, @DrVKGadi and @BCJoyceO discuss: https://t.co/hW2vgUG3Sj #breastcancerindex #casestudy ()